Gemcitabine

Gemcitabine is a clinically approved chemotherapeutic agent and a combination chemotherapy component that acts as a partner drug in multi-agent regimens, including neoadjuvant treatment with cisplatin and durvalumab-containing therapy in durvalumab-based protocols. It is used across solid tumors, especially in settings with DNA damage repair aberrations, renal medullary carcinoma, and pancreatic tumor delivery strategies, and it has also been evaluated with camonsertib, ixazomib, and igel. Key facts indicate it was used in both study arms as neoadjuvant treatment, underscoring its role as a backbone cytotoxic agent rather than a single-agent targeted therapy. Recent literature highlights low-dose gemcitabine combinations in preclinical and phase Ib studies, nanoparticle co-encapsulation to reduce systemic toxicity, and a phase II regimen with ixazomib and doxorubicin. Overall, the evidence emphasizes gemcitabine’s utility as a broadly deployed chemotherapy scaffold for combination regimens, with ongoing optimization for efficacy and tolerability.

Solid Tumors / DNA Damage Response

  • Low-dose gemcitabine combined with camonsertib was studied in preclinical models and in a phase Ib clinical evaluation for solid tumors with DNA damage repair aberrations. (PMID:41563386)
  • The camonsertib-gemcitabine study specifically focused on tumors with DNA damage response aberrations, supporting use in genomically selected populations. (PMID:41563386)
  • Gemcitabine remained part of combination chemotherapy rather than a standalone targeted agent in this setting. (PMID:41563386)

Bladder Cancer / Neoadjuvant Therapy

  • Gemcitabine was used with cisplatin in the neoadjuvant regimen compared against durvalumab-containing therapy in NIAGARA. (PMID:41678313)
  • The FDA approval summary for durvalumab notes gemcitabine as part of the adult muscle-invasive bladder cancer treatment backbone. (PMID:41678313)
  • Key facts indicate gemcitabine served as a combination chemotherapy component used in both study arms as neoadjuvant treatment. (PMID:41678313)

Drug Delivery / Toxicity Reduction

  • Gemcitabine was co-encapsulated in the igel nanoparticle and delivered after losartan preconditioning in a pancreatic tumor model. (PMID:41763269)
  • This delivery strategy reduced systemic toxicity while maintaining chemotherapy delivery. (PMID:41763269)
  • The study frames gemcitabine as a payload amenable to exosome-biomimetic or nanoparticle-based delivery approaches. (PMID:41763269)

Renal Medullary Carcinoma / Multi-Drug Combinations

  • In a phase II study, gemcitabine was combined with ixazomib and doxorubicin for SMARCB1-deficient renal medullary carcinoma. (PMID:42007903)
  • The regimen reflects gemcitabine’s continued use in aggressive rare cancers as part of multi-agent chemotherapy. (PMID:42007903)
  • The trial adds clinical evidence for triplet combinations incorporating gemcitabine in difficult-to-treat disease. (PMID:42007903)

Combination Screening / Negative Synergy

  • Gemcitabine was evaluated with kk2269, but the combination did not show significant antitumor activity. (PMID:41989931)
  • This finding suggests not all gemcitabine-based combinations produce additive or synergistic effects. (PMID:41989931)
  • The result helps define combination partners where gemcitabine may not enhance efficacy. (PMID:41989931)